Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 12 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

22%

2 of 9 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1
10(83.3%)
Phase 2
2(16.7%)
12Total
Phase 1(10)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials
NCT02434276Phase 2Unknown

Study of the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (VAX2012Q) in Adults 18-64 Years

Role: lead

NCT02247362Phase 1Unknown

Study of Safety and Immunogenicity of a Quadrivalent Influenza Vaccine in Healthy Adults Age 65-75 Years

Role: lead

NCT01658800Phase 1Completed

Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49

Role: lead

NCT02015494Phase 1Unknown

Phase 1 Safety Study of Recombinant Influenza Vaccine for Prevention

Role: lead

NCT00966238Phase 2Completed

Safety and Immunogenicity of VAX125 Influenza Vaccine in Community-living Adults >= 65 Years of Age

Role: lead

NCT00921206Phase 1Completed

Study to Investigate the Immune Response to Two Doses of VAX102 Healthy Adults

Role: lead

NCT00603811Phase 1Completed

Phase I Safety and Immunogenicity Study of VAX102 [Flagellin.HuM2e] Influenza Vaccine in Healthy Adults

Role: lead

NCT00730457Phase 1Completed

Phase 1 Safety and Immunogenicity Study in Healthy Adults of VAX125, a Recombinant HA-flagellin Influenza Vaccine

Role: lead

NCT00921973Phase 1Completed

Safety of VAX102 Vaccine Given With Seasonal Flu Vaccine in Healthy Adults

Role: lead

NCT01560793Phase 1Completed

Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years

Role: lead

NCT01172054Phase 1Completed

Comparative Safety and Immunogenicity of VAX128A, VAC128B and VAX128C Novel H1N1 Influenza Vaccine in Healthy Adults

Role: lead

NCT00921947Phase 1Completed

Comparative Safety and Immunogenicity of 1.0 µg Intramuscular (i.m.) and 2.0 µg Subcutaneous (s.c.) Dosing With VAX102 (M2e-flagellin) Universal Influenza Vaccine in Healthy Adults

Role: lead

All 12 trials loaded